Orally active progestogen with antiandrogenic activity; has been used in combinations as an oral contraceptive. Prepn: Brückner, DE 1075114 (1960 to E. Merck, AG); Brückner et al., Ber. 94, 1225 (1961); Sciaky, Gazz. Chim. Ital. 91, 545 (1961); GB 932153; H. J. Ringold, A. Bowers, US 3485852 (1963, 1969 both to Syntex). Endocrinological activities: D. M. Brennan, R. J. Kraay, Acta Endocrinol. 44, 367 (1963). Metabolism: S. Honma et al., Chem. Pharm. Bull. 25, 2019 (1977). Clinical evaluation in prostatic carcinoma: R. Nishimura, K. Shida, Prostate, Suppl. 1, 27 (1981); in benign prostatic hypertrophy: T. Usui et al., Acta Urol. Jpn. 27, 327 (1981), B.A. 73, 27225 (1982). Review of carcinogenicity studies: IARC Monographs 21, 365-375 (1979).
Progestogen; antineoplastic (hormonal).
Antineoplastic (Hormonal); Progestogens; Progestogen